‹ All Posts
Finkhoz Roboadvisory Services

26 mins ago · SEBI Registration INH000022297

Biocon gains as EU approves breast cancer biosimilar

BIOCON Limited (BIOCON) rose as much as 2.35% to an early high of ₹363.30 on November 18, even as the Sensex fell over 650 points. The European Commission granted marketing approval for Pebrilzo, Biocon’s biosimilar of the breast cancer drug Perjeta (pertuzumab), across the European Union. Pebrilzo is the first biosimilar to win European approval under the European Medicines Agency’s new tailored clinical approach, which relies more on lab and pharmacology data than large clinical trials. The approval came two days after the US FDA cleared Pebrilzo on November 16, making it Biocon’s fifth oncology biosimilar approved in the US. Biocon has also signed a 10-year supply deal for pertuzumab in Brazil. The new approval pathway is the bigger long-term positive. If more biosimilars can be approved with smaller trials, Biocon can bring products to market faster and at lower development cost. Approvals in Europe, the US and Brazil in quick succession also strengthen its oncology portfolio, which treats HER2-positive breast cancer across multiple stages. The revenue impact will take time. Under its settlement with Genentech, Biocon cannot launch Pebrilzo in the US until the third quarter of calendar 2028. In Europe, it will face price competition from established biosimilar makers like Sandoz and Pfizer. The EU approval was also widely expected after a positive committee recommendation in September, which explains the modest move. Investors should watch the timing of Pebrilzo’s European launch, pricing and market share in Europe, progress on other pipeline biosimilars, and Biocon Biologics’ profitability. The key question is whether Biocon can turn a string of approvals into meaningful revenue before 2028. Disclosure: I do not hold any position in Biocon Limited. This post is for informational purposes only and is not investment advice.

#StockInNews#WatchOutFor#FundamentalViews